Early Biomarkers of Bronchopulmonary Dysplasia: A Quick Look to the State of the Art

Abstract

Bronchopulmonary dysplasia (BPD) is one of the most common pulmonary sequelae of extreme preterm birth, with long-lasting respiratory symptoms and reduced lung function. A reliable predictive tool of BPD development is urgent and its search remains one of the major challenges for neonatologists approaching the upcoming arrival of possible new preventive therapies. Biomarkers, identifying an ongoing pathogenetic pathway, could allow both the selection of preterm infants with an evolving disease and potentially the therapeutic targets of the indicted pathogenesis. The “omic” sciences represent well-known promising tools for this objective. In this review, we resume the current laboratoristic, metabolomic, proteomic, and microbiomic evidence in the prediction of BPD.

Key Points

• The early prediction of BPD development would allow the targeted implementation of new preventive therapies.

• BPD is a multifactorial disease consequently it is unlikely to find a single disease biomarker.

• “Omic” sciences offer a promising insight in BPD pathogenesis and its development's fingerprints.

Keyword

bronchopulmonary dysplasia - biomarkers - preterm

Publication History

Article published online:
05 December 2022

• References

• 1 Stoll BJ, Hansen NI, Bell EF. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA 2015; 314 (10) 1039-1051
• 2 Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357 (19) 1946-1955
• 3 Bonadies L, Papi A, Baraldi E. Is bronchopulmonary dysplasia in adult age a novel COPD endotype?. Eur Respir J 2022; 60 (03) 2200984
• 4 Crump C, Howell EA, Stroustrup A, McLaughlin MA, Sundquist J, Sundquist K. Association of preterm birth with risk of ischemic heart disease in adulthood. JAMA Pediatr 2019; 173 (08) 736-743
• 5 Bonadies L, Zaramella P, Porzionato A, Muraca M, Baraldi E. Bronchopulmonary dysplasia: what's new on the horizon?. Lancet Child Adolesc Health 2018; 2 (08) 549-551
• 6 Bonadies L, Zaramella P, Porzionato A, Perilongo G, Muraca M, Baraldi E. Present and future of bronchopulmonary dysplasia. J Clin Med 2020; 9 (05) 1539
• 7 Álvarez-Fuente M, Moreno L, Mitchell JA. et al. Preventing bronchopulmonary dysplasia: new tools for an old challenge. Pediatr Res 2019; 85 (04) 432-441
• 8 Ambalavanan N, Carlo WA, D'Angio CT. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 2009; 123 (04) 1132-1141
• 9 Kotecha S, Wilson L, Wangoo A, Silverman M, Shaw RJ. Increase in interleukin (IL)-1 β and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 1996; 40 (02) 250-256
• 10 Jónsson B, Tullus K, Brauner A, Lu Y, Noack G. Early increase of TNF α and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 77 (03) F198-F201
• 11 Baier RJ, Majid A, Parupia H, Loggins J, Kruger TE. CC chemokine concentrations increase in respiratory distress syndrome and correlate with development of bronchopulmonary dysplasia. Pediatr Pulmonol 2004; 37 (02) 137-148
• 12 Bourbia A, Cruz MA, Rozycki HJ. NF-kappaB in tracheal lavage fluid from intubated premature infants: association with inflammation, oxygen, and outcome. Arch Dis Child Fetal Neonatal Ed 2006; 91 (01) F36-F39
• 13 Capoluongo E, Vento G, Lulli P. et al. Epithelial lining fluid neutrophil-gelatinase-associated lipocalin levels in premature newborns with bronchopulmonary dysplasia and patency of ductus arteriosus. Int J Immunopathol Pharmacol 2008; 21 (01) 173-179
• 14 Contreras M, Hariharan N, Lewandoski JR, Ciesielski W, Koscik R, Zimmerman JJ. Bronchoalveolar oxyradical inflammatory elements herald bronchopulmonary dysplasia. Crit Care Med 1996; 24 (1, suppl): 29-37
• 15 Gladstone Jr IM, Levine RL. Oxidation of proteins in neonatal lungs. Pediatrics 1994; 93 (05) 764-768
• 16 Collard KJ, Godeck S, Holley JE, Quinn MW. Pulmonary antioxidant concentrations and oxidative damage in ventilated premature babies. Arch Dis Child Fetal Neonatal Ed 2004; 89 (05) F412-F416
• 17 Joung KE, Kim HS, Lee J. et al. Correlation of urinary inflammatory and oxidative stress markers in very low birth weight infants with subsequent development of bronchopulmonary dysplasia. Free Radic Res 2011; 45 (09) 1024-1032
• 18 Mohamed WAW, Niyazy WH, Mahfouz AA. Angiopoietin-1 and endostatin levels in cord plasma predict the development of bronchopulmonary dysplasia in preterm infants. J Trop Pediatr 2011; 57 (05) 385-388
• 19 Janér J, Andersson S, Kajantie E, Lassus P. Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants. Pediatrics 2009; 123 (04) 1142-1146
• 20 Tsao PN, Wei SC, Su YN. et al. Placenta growth factor elevation in the cord blood of premature neonates predicts poor pulmonary outcome. Pediatrics 2004; 113 (5, 5I): 1348-1351
• 21 Vento G, Capoluongo E, Matassa PG. et al. Serum levels of seven cytokines in premature ventilated newborns: correlations with old and new forms of bronchopulmonary dysplasia. Intensive Care Med 2006; 32 (05) 723-730
• 22 Hasan J, Beharry KD, Valencia AM, Strauss A, Modanlou HD. Soluble vascular endothelial growth factor receptor 1 in tracheal aspirate fluid of preterm neonates at birth may be predictive of bronchopulmonary dysplasia/chronic lung disease. Pediatrics 2009; 123 (06) 1541-1547
• 23 Ogihara T, Hirano K, Morinobu T. et al. Plasma KL-6 predicts the development and outcome of bronchopulmonary dysplasia. Pediatr Res 2006; 60 (05) 613-618
• 24 Schrama AJJ, Bernard A, Poorthuis BJHM, Zwinderman AH, Berger HM, Walther FJ. Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia. Eur J Pediatr 2008; 167 (11) 1305-1312
• 25 Sarafidis K, Stathopoulou T, Diamanti E. et al. Clara cell secretory protein (CC16) as a peripheral blood biomarker of lung injury in ventilated preterm neonates. Eur J Pediatr 2008; 167 (11) 1297-1303
• 26 Ramsay PL, DeMayo FJ, Hegemier SE, Wearden ME, Smith CV, Welty SE. Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 164 (01) 155-161
• 27 Kotecha S, Wangoo A, Silverman M, Shaw RJ. Increase in the concentration of transforming growth factor beta-1 in bronchoalveolar lavage fluid before development of chronic lung disease of prematurity. J Pediatr 1996; 128 (04) 464-469
• 28 Fanos V, Pintus MC, Lussu M. et al. Urinary metabolomics of bronchopulmonary dysplasia (BPD): preliminary data at birth suggest it is a congenital disease. J Matern Fetal Neonatal Med 2014; 27 (2, suppl 2): 39-45
• 29 Baraldi E, Giordano G, Stocchero M. et al. Untargeted metabolomic analysis of amniotic fluid in the prediction of preterm delivery and bronchopulmonary dysplasia. PLoS One 2016; 11 (10) e0164211
• 30 La Frano MR, Fahrmann JF, Grapov D. et al. Umbilical cord blood metabolomics reveal distinct signatures of dyslipidemia prior to bronchopulmonary dysplasia and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2018; 315 (05) L870-L881
• 31 Pintus MC, Lussu M, Dessì A. et al. Urinary ¹H-NMR metabolomics in the first week of life can anticipate BPD diagnosis. Oxid Med Cell Longev 2018; 2018: 7620671
• 32 Piersigilli F, Lam TT, Vernocchi P. et al. Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics. Metabolomics 2019; 15 (02) 20
• 33 Rogosch T, Herrmann N, Maier RF. et al. Detection of bloodstream infections and prediction of bronchopulmonary dysplasia in preterm neonates with an electronic nose. J Pediatr 2014; 165 (03) 622-624
• 34 Charitharth Vivek Lal NA. Biomarkers, early diagnosis, and clinical predictors of BPD. Clin Perinatol 2016; 42 (04) 739-754
• 35 Magagnotti C, Matassa PG, Bachi A. et al. Calcium signaling-related proteins are associated with broncho-pulmonary dysplasia progression. J Proteomics 2013; 94: 401-412
• 36 Förster K, Sass S, Ehrhardt H. et al. Early identification of bronchopulmonary dysplasia using novel biomarkers by proteomic screening. Am J Respir Crit Care Med 2017; 197 (08) 1076-1080
• 37 Zasada M, Suski M, Bokiniec R. et al. Comparative two time-point proteome analysis of the plasma from preterm infants with and without bronchopulmonary dysplasia. Ital J Pediatr 2019; 45 (01) 112
• 38 Arjaans S, Wagner BD, Mourani PM. et al. Early angiogenic proteins associated with high risk for bronchopulmonary dysplasia and pulmonary hypertension in preterm infants. Am J Physiol Lung Cell Mol Physiol 2020; 318 (04) L644-L654
• 39 Ballard PL, Oses-Prieto J, Chapin C, Segal MR, Ballard RA, Burlingame AL. Composition and origin of lung fluid proteome in premature infants and relationship to respiratory outcome. PLoS One 2020; 15 (12) e0243168
• 40 Lal CV, Bhandari V, Ambalavanan N. Genomics, microbiomics, proteomics, and metabolomics in bronchopulmonary dysplasia. Semin Perinatol 2018; 42 (07) 425-431
• 41 Mourani PM, Harris JK, Sontag MK, Robertson CE, Abman SH. Molecular identification of bacteria in tracheal aspirate fluid from mechanically ventilated preterm infants. PLoS One 2011; 6 (10) e25959
• 42 Lohmann P, Luna RA, Hollister EB. et al. The airway microbiome of intubated premature infants: characteristics and changes that predict the development of bronchopulmonary dysplasia. Pediatr Res 2014; 76 (03) 294-301
• 43 Lal CV, Travers C, Aghai ZH. et al. The airway microbiome at birth. Sci Rep 2016; 6: 31023
• 44 Wagner BD, Sontag MK, Harris JK. et al. Airway microbial community turnover differs by BPD severity in ventilated preterm infants. PLoS One 2017; 12 (01) e0170120
• 45 Moschino L, Bonadies L, Baraldi E. Lung growth and pulmonary function after prematurity and bronchopulmonary dysplasia. Pediatr Pulmonol 2021; 56 (11) 3499-3508